Format

Send to

Choose Destination
J Thromb Haemost. 2018 Dec;16(12):2391-2396. doi: 10.1111/jth.14305. Epub 2018 Oct 15.

Management of venous thromboembolism in patients with cancer.

Author information

1
Department of Internal Medicine, Hospital de Badalona Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, Spain.
2
Department of Internal Medicine, Hospital General Universitario Santa Lucía, Universidad Católica San Antonio de Murcia (UCAM), Murcia, Spain.

Abstract

Current guidelines for anticoagulant therapy do not so far suggest any form of differentiated approach to cancer patients with venous thromboembolism (VTE). This review article provides an overview of the published literature in cancer patients with VTE, mostly using data from the RIETE registry. Our findings provide some insights into what factors may be used to guide physicians in adapting recommended anticoagulant regimens to the individual patient, as oncologists are increasingly doing with cancer treatments. For instance, patients presenting with deep vein thrombosis (DVT) alone might benefit from curtailing treatment intensity as anticoagulant therapy progresses. The site of cancer also needs to be considered. In patients with incidental PE or splanchnic vein thrombosis, we should be more cautious before prescribing anticoagulant therapy. The optimal duration of anticoagulant therapy is unknown.

KEYWORDS:

anticoagulant therapy; bleeding; cancer; death; recurrences; venous thromboembolism

PMID:
30246407
DOI:
10.1111/jth.14305

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center